ImmunityBio 股價、新聞與催化劑

股票表現

股價為何變動

最新公司動態「ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ」發布後，IBRX 於 2026年11月4日 收於 $8.93，較前一交易日上漲 7.72%。該變動發生在與這則商業化動態對應的交易時段。

公司概覽

未來催化劑

• 2026年BCG-naive癌原位ANKTIVA的補充BLA提交。

近期新聞

1. 01
   2026-11-04 13:00 EST

   ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

2. 02
   2026-10-21 11:30 EST

   ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

3. 03
   2026-10-16 15:49 EST

   ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

4. 04
   2026-10-14 20:18 EST

   FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

5. 05
   2026-10-08 12:30 EST

   ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

相似股票

商業成熟度、治療領域或催化劑模式相近的同業公司。